Cap: Patients with hepatic or severe renal dysfunction.
Tab: Gallbladder disease; history of hypersensitivity to fenofibrate, including severe skin rashes (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis); liver disease, active, including primary biliary cirrhosis and unexplained persistent liver function abnormality; nursing mothers; severe renal dysfunction, including patients receiving dialysis.